FDA Warning Letter Cites Quality Control Issues At Abbott Diabetes Care
This article was originally published in The Gray Sheet
Abbott's Diabetes Care division did not follow internal protocols for quality control testing of its FreeStyle blood glucose monitoring systems and FreeStyle Navigator continuousglucose monitoring systems, FDA alleged in a July 2 warning letter to the firm
You may also be interested in...
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.